Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.21 USD
Change Today -0.05 / -0.69%
Volume 263.6K
RPRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

repros therapeutics inc (RPRX) Snapshot

Open
$7.22
Previous Close
$7.26
Day High
$7.45
Day Low
$7.15
52 Week High
09/2/14 - $22.55
52 Week Low
10/21/14 - $5.92
Market Cap
175.0M
Average Volume 10 Days
263.4K
EPS TTM
$-1.36
Shares Outstanding
24.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REPROS THERAPEUTICS INC (RPRX)

repros therapeutics inc (RPRX) Related Bloomberg News

View More Bloomberg News

repros therapeutics inc (RPRX) Related Businessweek News

No Related Businessweek News Found

repros therapeutics inc (RPRX) Details

Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase IIB clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.

26 Employees
Last Reported Date: 05/7/15
Founded in 1987

repros therapeutics inc (RPRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $891.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $325.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $250.0K
Chief Medical Officer
Total Annual Compensation: $200.0K
Vice President of Research & Development
Total Annual Compensation: $190.0K
Compensation as of Fiscal Year 2014.

repros therapeutics inc (RPRX) Key Developments

Repros Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Repros Therapeutics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, net loss was $8.5 million, or $0.35 per share, as compared to a net loss of $8.8 million, or $0.38 per share, for the same period in 2014. The decrease in net loss for the three month period ended March 31, 2015 as compared to the same period in 2014 was primarily due to decreased clinical development expenses related to the company's enclomiphene product candidate, formerly known as Androxal, partially offset by increases in clinical development expenses related to Proellex, research and development payroll and benefits expenses and increased legal expenses. Research and development expenses decreased 3%, or approximately $248,000, to $7.3 million for the three month period ended March 31, 2015, as compared to $7.6 million for the same period in the prior year. Interest income decreased to $1,000 as compared to $2,000 for the same period in the prior year. The decrease for the three month period ended March 31, 2015 as compared to the same period in the prior year was primarily due to decreased cash balances.

Repros Therapeutics Inc. Announces November 30, 2015 PDUFA Goal Date for New Drug Application

Repros Therapeutics Inc. announced that the U.S. Food and Drug Administration assigned a Prescription Drug User Fee Act goal date of November 30, 2015, for substantive review of the company's New Drug Application for its enclomiphene citrate product candidate, formerly known as Androxal. In addition, the FDA has informed the company that the FDA is currently planning to hold an advisory committee meeting on the NDA during the review.

Repros Therapeutics Inc., Annual General Meeting, May 28, 2015

Repros Therapeutics Inc., Annual General Meeting, May 28, 2015., at 09:00 Central Standard Time. Location: The Woodlands Waterway Marriott Hotel and Convention Center, 1601 Lake Robbins Drive. Agenda: To consider the election of a board of six directors; to approve the appointment of PricewaterhouseCoopers LLP as company' registered independent public accounting firm for the fiscal year ending December 31, 2015; and to approve on an advisory basis, of the compensation of company' named executive officers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPRX:US $7.21 USD -0.05

RPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPRX.
View Industry Companies
 

Industry Analysis

RPRX

Industry Average

Valuation RPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPROS THERAPEUTICS INC, please visit www.reprosrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.